Nymox Pharmaceutical Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2022	2021	2020	2019	2018	2017 - 1997
Market Capitalization	21	30	110	177	142	74	Upgrade
Market Cap Growth	-71.21%	-73.14%	-37.81%	24.13%	92.66%	-54.43%	Upgrade
Enterprise Value	21	28	109	173	137	66	Upgrade
PE Ratio	-	-4.49	-8.76	-15.05	-10.81	-6.97	Upgrade
PS Ratio	-	-	-	35324.48	1226.62	247.01	Upgrade
PB Ratio	-17.25	-61.22	-217.08	82.34	41.27	10.55	Upgrade
P/FCF Ratio	-15.60	-5.67	-11.18	-17.57	-19.15	-9.42	Upgrade
P/OCF Ratio	-15.62	-5.67	-11.19	-17.60	-19.15	-9.47	Upgrade
EV/Sales Ratio	-	-	-	34687.48	1182.72	220.43	Upgrade
EV/EBITDA Ratio	-11.84	-4.50	-8.94	-15.18	-10.92	-6.23	Upgrade
EV/EBIT Ratio	-10.83	-4.33	-8.75	-14.83	-10.45	-6.23	Upgrade
EV/FCF Ratio	-15.48	-5.43	-11.13	-17.26	-18.47	-8.41	Upgrade
Debt / Equity Ratio	-0.06	-0.36	-0.77	0.20	0.04	-	Upgrade
Debt / EBITDA Ratio	-0.04	-0.03	-0.03	-0.04	-0.01	-	Upgrade
Debt / FCF Ratio	-0.06	-0.03	-0.04	-0.04	-0.02	-	Upgrade
Quick Ratio	0.15	0.67	0.47	1.85	2.58	7.41	Upgrade
Current Ratio	0.19	0.69	0.58	1.98	2.61	7.47	Upgrade
Asset Turnover	0	0	0	0.00	0.01	0.06	Upgrade
Interest Coverage	-86.18	-151.93	-320.46	-278.48	-345.37	-587.56	Upgrade
Return on Equity (ROE)	-1589.50%	-2321.60%	-868.80%	-737.50%	-196.80%	-315.30%	Upgrade
Return on Assets (ROA)	-117.20%	-251.00%	-373.70%	-323.60%	-153.60%	-223.30%	Upgrade
Return on Capital (ROIC)	175.85%	2152.75%	10873.04%	-455.85%	-370.65%	-151.97%	Upgrade
Earnings Yield	-13.42%	-22.29%	-11.41%	-6.65%	-9.25%	-14.34%	Upgrade
FCF Yield	-9.28%	-17.64%	-8.95%	-5.69%	-5.22%	-10.61%	Upgrade
Buyback Yield / Dilution	-5.22%	-9.04%	-11.04%	-7.23%	-13.86%	-14.85%	Upgrade
Total Shareholder Return	-5.22%	-9.04%	-11.04%	-7.23%	-13.86%	-14.85%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).